

Press release

Zug, 20 November 2009

Disclosure of shareholdings according to articles 9 and 21 of the Stock Exchange Ordinance of the Swiss Financial Market Supervisory Authority FINMA

HBM BioVentures Ltd. (SIX: HBMN), Zug, announces that it received a notification from OSI Pharmaceuticals Inc., 41 Pinelawn Road, Melville, NY 11747, USA, on 19 November 2009 that OSI Pharmaceuticals Inc. has acquired further shares of HBM BioVentures Ltd. and, as a result, exceeded the threshold of 5% voting rights on 18 November by owning 570'173 registered shares of HBM BioVentures Ltd..

The 570'173 registered shares correspond to 5.33% of the voting rights of HBM BioVentures Ltd., since the reduction of the share capital, which had been approved by the shareholders' meeting on 4 September 2009, was entered in the commercial register on 18 November 2009. The share capital of HBM BioVentures Ltd. is CHF 642 million and is divided into 10'700'000 shares with a par value of CHF 60 each.

For further information, please contact Dr. Andreas Wicki, CEO HBM BioVentures Ltd., Tel.: +41 41 768 11 08, andreas.wicki@hbmbioventures.com.

Brief profile of HBM BioVentures Ltd

As a venture capital company, HBM BioVentures is invested globally in some 35 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The lead products of many of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on emerging companies that are not yet listed, with two-thirds of assets invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and

HBM BioVentures AG
Bundesplatz 1
CH-6300 Zug/ Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hbmbioventures.com
www.hbmbioventures.com

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM BioVentures AG
Bundesplatz 1
CH-6300 Zug/ Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hbmbioventures.com
www.hbmbioventures.com